Montelukast Accord (Montelukast Sodium)

Montelukast, the active ingredient in Montelukast Accord, is a leukotriene receptor antagonist presented as a tablet for oral use. It treats asthma, allergic rhinitis, and exercise‑induced bronchoconstriction in adults and children.

GNH USA supplies Montelukast Accord as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Montelukast is a leukotriene receptor antagonist that modulates inflammatory pathways in respiratory disorders.

- Asthma: improves long‑term control and reduces the frequency of exacerbations. - Allergic rhinitis: relieves nasal congestion, sneezing and itchy eyes. - Exercise‑induced bronchoconstriction: prevents airway narrowing during physical activity.

Montelukast is generally well tolerated, but adverse reactions can occur.

Common Side Effects: - Headache - Abdominal pain - Cough - Nasopharyngitis

Serious or Rare Side Effects: - Allergic reactions such as angioedema or urticaria - Neuropsychiatric events including agitation, depression or suicidal thoughts - Elevation of hepatic enzymes - Eosinophilic granulomatosis with polyangiitis

Before prescribing Montelukast, clinicians should consider several safety aspects.

- Assess asthma control before initiating: ensure the patient is on appropriate inhaled therapy. - Monitor for neuropsychiatric symptoms: report any mood changes or suicidal thoughts promptly. - Avoid use in patients with known hypersensitivity to montelukast or its excipients. - Use with caution in hepatic impairment: consider dose adjustment if necessary. - Store at ambient temperature below 25°C: keep in the original pack, protect from moisture.

Montelukast may interact with other medicines, requiring attention to potential changes in efficacy or safety.

Major Interactions (Avoid): - Phenobarbital, rifampin, carbamazepine: may markedly reduce montelukast plasma concentrations. - Erythromycin, ketoconazole: may increase montelukast levels and risk of side effects.

Moderate Interactions (Monitor Closely): - Warfarin: possible alteration of INR; monitor coagulation parameters. - Theophylline: additive bronchodilator effect; observe clinical response. - Beta‑agonists: no significant pharmacokinetic interaction, but monitor overall asthma control.